Zacks Research Estimates Novavax’s Q2 Earnings (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for shares of Novavax in a note issued to investors on Tuesday, January 28th. Zacks Research analyst S. Ganoria now expects that the biopharmaceutical company will earn $0.44 per share for the quarter, up from their previous forecast of $0.39. The consensus estimate for Novavax’s current full-year earnings is ($1.31) per share. Zacks Research also issued estimates for Novavax’s Q2 2026 earnings at $0.07 EPS and FY2026 earnings at $0.39 EPS.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same period in the prior year, the company posted ($1.26) earnings per share. The firm’s revenue was down 54.8% compared to the same quarter last year.

A number of other brokerages have also commented on NVAX. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. Jefferies Financial Group cut their price target on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 16th. Finally, B. Riley reissued a “buy” rating and set a $26.00 price objective (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $17.83.

Novavax Price Performance

Shares of Novavax stock opened at $8.81 on Thursday. The firm has a fifty day moving average price of $8.81 and a two-hundred day moving average price of $10.84. Novavax has a fifty-two week low of $3.53 and a fifty-two week high of $23.86.

Institutional Trading of Novavax

Several large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Novavax by 16.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company’s stock worth $16,741,000 after acquiring an additional 187,548 shares in the last quarter. Bank of Montreal Can boosted its stake in Novavax by 26.7% in the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock worth $32,643,000 after purchasing an additional 517,727 shares in the last quarter. State Street Corp grew its holdings in shares of Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after purchasing an additional 1,621,772 shares during the last quarter. Vontobel Holding Ltd. increased its stake in shares of Novavax by 110.3% in the third quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company’s stock valued at $6,296,000 after buying an additional 261,464 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Novavax by 300.4% in the third quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company’s stock valued at $1,226,000 after buying an additional 72,894 shares during the last quarter. 53.04% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the sale, the director now owns 14,770 shares of the company’s stock, valued at approximately $133,225.40. This represents a 21.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James F. Young sold 5,400 shares of Novavax stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at $414,080. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,150 shares of company stock valued at $119,641 over the last quarter. Corporate insiders own 1.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.